Navigation Links
CV Therapeutics' Anti-Ischemic Agent Ranexa(R) Significantly Reduces HbA1c and Other Markers of Diabetes in MERLIN TIMI-36
Date:11/6/2007

ardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

CV Therapeutics also has other clinical and preclinical drug development candidates and programs, including regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies, and CVT-6883, which is being developed as a potential treatment for cardiopulmonary diseases. Regadenoson and CVT-6883 have not been determined by any regulatory authorities to be safe or effective in humans for any use.

Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including operating losses and fluctuations in operating results; capital requirements; regulatory review and approval of our products; special protocol assessment agreement; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; concentrated customer base; reliance on strategic partnerships and collaborations; uncertainties in drug development; uncertainties regarding intellectual property; and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2007. CV Therapeutics disclaims any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE CV Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2008)... to Have Higher Sensitivity and Specificity, than...was the preferred test in all phas... 13 /- AT First Diagnostic LLC an,eme...ic test kits, today,announced that a recent evalua...f Research of the FirstVue(TM) HBSAG Test, was rel...
(Date:10/13/2008)...- Facet Solutions, Inc. today,announc...nts from its US,IDE Pilot Study. The results show ... scores, and an 80% reduction in Visual Analog Sco...resident & CEO for Facet Solutions,added, "We are... far not,only demonstrate significant pain relief ...
(Date:10/12/2008)...N, Oct. 12 /- Boston,Scient...ults from an analysis,of nearly 7,500 patients fro...esigned to confirm the performance of the TAXUS(R)...stem in real-world practice. The,two-year pooled A...nical,restenosis in patients with diabetes as effe...
(Date:10/10/2008)...is Treatment with Kogenate FS Reduces the,Risk of ...No Pre-Existing,Joint Damage, BERKELEY, Calif., O...ced today that the U.S. Food and Drug Administrati...enate(R) FS Antihemophilic Factor,(Recombinant) to... risk of,joint damage in patients aged 0-16 years ...
Breaking Medicine Technology:Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 2Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 3Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 4TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 2TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 3TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 4TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 5FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 2FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 3FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 4FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 5Shingles Pain Treatment Will Benefit More Patients 2872 1Shingles Pain Treatment Will Benefit More Patients 2872 2Shingles Pain Treatment Will Benefit More Patients 2872 3Shingles Pain Treatment Will Benefit More Patients 2872 4Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout RDEA594 Into Phase 1 Clinical Trial 2867 1Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout RDEA594 Into Phase 1 Clinical Trial 2867 2Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout RDEA594 Into Phase 1 Clinical Trial 2867 3Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout RDEA594 Into Phase 1 Clinical Trial 2867 4Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 1Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 2Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 3Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 4Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 5Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 6Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 7Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 8Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 9Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 10Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 11Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 12Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 13Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 14Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 15Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 16Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 17Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 18Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 19Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 20Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 21New Health Knowledge Base and Semantic Search Engine Announced 25637 1New Health Knowledge Base and Semantic Search Engine Announced 25637 2
...d Insurance Coverage Varies,Greatly for Different ... 2007-- Most U.S. adults support,approving the use...act people,s quality of life, including birth cont...reat erectile,dysfunction and improve memory and t...ieve these types of treatments should be covered,b...
...y 1, 2007 - Progenics,Pharmaceuticals, Inc. (NASDA... first clinical trial of its investigational drug,...mmunodeficiency,virus (HIV), the causative agent o... of PRO 140 achieved an average maximum,decrease o...,log10), with individual reductions ranging up to ...
Other Medicine Technology:Eighty-one Percent of U.S. Adults say that Birth Control Pills and,Procedures Should Be Covered by Health Insurance 2Eighty-one Percent of U.S. Adults say that Birth Control Pills and,Procedures Should Be Covered by Health Insurance 3Eighty-one Percent of U.S. Adults say that Birth Control Pills and,Procedures Should Be Covered by Health Insurance 4Progenics Announces Positive Results in Clinical Trial of Novel HIV,Therapy 2Progenics Announces Positive Results in Clinical Trial of Novel HIV,Therapy 3Progenics Announces Positive Results in Clinical Trial of Novel HIV,Therapy 4Progenics Announces Positive Results in Clinical Trial of Novel HIV,Therapy 5Progenics Announces Positive Results in Clinical Trial of Novel HIV,Therapy 6Progenics Announces Positive Results in Clinical Trial of Novel HIV,Therapy 7
(Date:10/13/2008)...ges Latinos to Get Tested, LOS ANGELES, Oct. 13 /...half of all newly diagnosed HIV/AIDS cases,reporte...ionally., -- A week of activities aimed at raisin...ting to coincide with National Latino AIDS Awarene...r Community, Our Responsibility: Latinos in Action...
(Date:10/13/2008)...n ever before, study finds , , MONDAY,...ver are being treated for high blood pressure, say...nd Blood Institute. , The major factor in the d...igh blood pressure appears to be the obesity epide...dditional efforts are needed to prevent hypertensi...
(Date:10/13/2008)...g advances study Study needed because of low... 13 /PRNewswire/ -- Advanced Circulatory Systems, ...ced today that it has received,an additional $1.5 ...,Health (NIH) to continue a study testing two devi...rdiac arrest outside a hospital. Parts of Oakland,...
(Date:10/13/2008)...valve.com ) announced today that the expanded clin...aneous aortic valve replacement (PAVR) in high-ris...l patients at an accelerating pace. More than 1,80...ly 100 centers in 20 countries. , ...er 13, 2008 -- During the Monday Transcatheter Ao...
Breaking Medicine News(10 mins):Health News:Nearly Half of Newly Diagnosed HIV/AIDS Cases in Los Angeles County Are Among Latinos 2Health News:Blood Pressure on the Rise in America 2Health News:Blood Pressure on the Rise in America 3Health News:3 Michigan Counties Participating in NIH Study of Cardiac Arrest Resuscitation Techniques 2Health News: CoreValve Announces That More Than 1,800 High-Risk Patients Have Been Treated with its ReValving System for Percutaneous Aortic Valve Replacement (PAVR) : Highly encouraging registry data also presented at TCT 2008 2
...ofi-Aventis, one of the world's leading pharmaceut... Taxotere (docetaxel) improves survival in patient... clinical trial named TAX 327 compared Taxotere pl...one) plus prednisone. The study included a little ...
...nagers who use mobile phones for many hours a day ...ay develop psychological disorders, says a study t...s. // Francisca Lopez Torrecillas, a lecturer at t...chological assessment and treatment of the Univers...
...ian belief and knowledge are great healers and 140...rently in Delhi to study this value system. // "Th...tal role in dealing with mental health issues and ...re about it," said Patrick Bantman, a psychiatrist...
...en aiming to shed after-pregnancy pounds should ad...cording to a new study by Harvard researchers. // ...isk for weight gain in women,” said lead author Em...n that early postpartum period — such as diet, tel...
Other Medicine News:Health News:Mobile Phone Addiction may Cause Psychological Problems 2Health News:Simple Solutions to Postpartum Weight Retention 2
Spinal Concepts has developed a versatile set of instruments intended to make posterior lumbar interbody fusion procedures precise, simple and quick every time. The Harmony PLIF Instrument Set is the
Kerrison (Spurling) Laminectomy Rongeur. 15 cm - 6, thick footplate, large handle, 90 up-cutting, 2 mm wide.
Kerrison (Micro) Laminectomie Rongeur, with ejector. 18 cm - 7 1/8, with thick footplate, small handle, 90 up-cutting, jaws 2 mm wide.
OSV II Smart ValveTM, Hakim, H-V Lumbar Valve system is the intelligent choice for meeting the complex demands of hydrocephalus shunting. Automatic pressure response causes the valve to adjust automa
Medicine Products: